Amphastar Pharmaceuticals Stock Hits New 12-Month Low After Analyst Downgrade

Shares of the pharmaceutical company fall after Wells Fargo cuts its price target

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its stock price reach a new 52-week low after Wells Fargo & Company lowered its price target on the stock from $34.00 to $30.00. The company's shares traded as low as $19.83 on the news, closing at $20.23 with a trading volume of 1,965,411 shares.

Why it matters

Amphastar Pharmaceuticals is a specialty pharmaceutical company that focuses on developing, manufacturing, and commercializing injectable and inhalation products. The company's stock price decline following the analyst downgrade reflects broader market concerns about the company's financial performance and growth prospects.

The details

Wells Fargo & Company maintained an "overweight" rating on Amphastar Pharmaceuticals but lowered its price target from $34.00 to $30.00. The downgrade comes after the company reported weaker-than-expected financial results in its most recent quarter. Amphastar has also faced increased competition in some of its key product markets, which has put pressure on its profit margins.

  • Amphastar Pharmaceuticals' stock price reached a new 52-week low on Saturday, February 28, 2026.

The players

Amphastar Pharmaceuticals, Inc.

A specialty pharmaceutical company headquartered in Rancho Cucamonga, California that focuses on the development, manufacturing, and commercialization of injectable and inhalation products.

Wells Fargo & Company

A major American financial services company that provides investment research and analysis on various stocks, including Amphastar Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The decline in Amphastar Pharmaceuticals' stock price following the analyst downgrade highlights the volatility and uncertainty facing the pharmaceutical industry, where companies must navigate increasing competition, regulatory changes, and shifting market dynamics to maintain profitability and growth.